Investment
Features
FeesSafety
Academy
More
Pluang+

Compare e l f Beauty Inc (ELF) vs GeneDx Holdings Corp (WGS) Price & Performance

e l f Beauty IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

e l f Beauty Inc vs GeneDx Holdings Corp — how do they compare? e l f Beauty Inc trades at $94.8 (market cap $5.62B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: e l f Beauty Inc is far larger — about 2.4× GeneDx Holdings Corp's market cap, and e l f Beauty Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

ELFWGS
Market Cap
$5.62B$2.32B
Sector
TechnologyTechnology
52-Week High
$146.67$167.51
52-Week Low
$49.57$34.51
Enterprise Value
$6.20B$2.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

e l f Beauty Inc

ELF trades at $98.49, up 6.69% in 24 hours, near its 52-week high. The stock exhibits a bullish technical trend with strong support at $93 and resistance at $101. Recent Q2 2026 earnings beat expectations with EPS of $1.75 versus $0.71 expected, driven by 36% revenue growth and the Rhode acquisition. The company raised fiscal 2027 guidance, reflecting robust demand and international expansion.

Outlook remains positive due to consistent sales growth and strategic initiatives, but risks include high valuation (P/E 97.18) and reliance on acquisitions for growth. The stock offers growth potential but faces margin pressure from increased investments and competitive dynamics in the beauty sector.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

About e l f Beauty Inc

e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.

Read more on ELF

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS